Editas Medicine
Market Cap
US$4.7b
Last Updated
2021/01/18 23:14 UTC
Data Sources
Company Financials +
Executive Summary
Editas Medicine, Inc. operates as a clinical stage genome editing company. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet and slightly overvalued.
Similar Companies
Share Price & News
How has Editas Medicine's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EDIT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: EDIT's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
Market Performance
7 Day Return
-1.0%
EDIT
3.2%
US Biotechs
-0.4%
US Market
1 Year Return
148.5%
EDIT
36.8%
US Biotechs
19.5%
US Market
Return vs Industry: EDIT exceeded the US Biotechs industry which returned 36.8% over the past year.
Return vs Market: EDIT exceeded the US Market which returned 19.6% over the past year.
Shareholder returns
| EDIT | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.0% | 3.2% | -0.4% |
| 30 Day | 18.2% | 4.8% | 2.3% |
| 90 Day | 129.5% | 22.4% | 12.7% |
| 1 Year | 148.5%148.5% | 39.0%36.8% | 22.3%19.5% |
| 3 Year | 119.9%119.9% | 27.5%20.8% | 44.4%34.8% |
| 5 Year | n/a | 46.3%35.2% | 128.7%103.3% |
Long-Term Price Volatility Vs. Market
How volatile is Editas Medicine's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 days ago | Simply Wall St
This Insider Has Just Sold Shares In Editas Medicine, Inc. (NASDAQ:EDIT)2 weeks ago | Simply Wall St
Here's Why We're Not At All Concerned With Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation1 month ago | Simply Wall St
Did Editas Medicine, Inc. (NASDAQ:EDIT) Insiders Sell Shares?Valuation
Is Editas Medicine undervalued compared to its fair value and its price relative to the market?
35.0%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EDIT ($76.14) is trading below our estimate of fair value ($117.19)
Significantly Below Fair Value: EDIT is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EDIT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: EDIT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EDIT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EDIT is overvalued based on its PB Ratio (10.7x) compared to the US Biotechs industry average (4.2x).
Next Steps
Future Growth
How is Editas Medicine forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
13.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EDIT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EDIT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EDIT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EDIT's revenue (46.5% per year) is forecast to grow faster than the US market (10.3% per year).
High Growth Revenue: EDIT's revenue (46.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EDIT is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Editas Medicine performed over the past 5 years?
-10.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EDIT is currently unprofitable.
Growing Profit Margin: EDIT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EDIT is unprofitable, and losses have increased over the past 5 years at a rate of 10.1% per year.
Accelerating Growth: Unable to compare EDIT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EDIT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: EDIT has a negative Return on Equity (-20.68%), as it is currently unprofitable.
Next Steps
Financial Health
How is Editas Medicine's financial position?
Financial Position Analysis
Short Term Liabilities: EDIT's short term assets ($506.8M) exceed its short term liabilities ($54.8M).
Long Term Liabilities: EDIT's short term assets ($506.8M) exceed its long term liabilities ($101.2M).
Debt to Equity History and Analysis
Debt Level: EDIT is debt free.
Reducing Debt: EDIT has no debt compared to 5 years ago when its debt to equity ratio was 1.4%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EDIT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: EDIT has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 34.9% each year.
Next Steps
Dividend
What is Editas Medicine current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EDIT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EDIT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EDIT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EDIT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EDIT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Cindy Collins (62 yo)
1.83yrs
Tenure
US$14,489,736
Compensation
Ms. Cynthia L. Collins, also Known as Cindy, MBA, serves as Director of Alliance for Regenerative Medicine. She has been a Director of Editas Medicine, Inc. since December 10, 2018 and its Chief Executive ...
CEO Compensation Analysis
Compensation vs Market: Cindy's total compensation ($USD14.49M) is above average for companies of similar size in the US market ($USD5.01M).
Compensation vs Earnings: Cindy's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.83yrs | US$14.49m | 0.023% $ 1.1m | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| CFO, Principal Accounting Officer | 1yr | no data | 0.030% $ 1.4m | |
| Senior Vice President of Operations | 1yr | no data | no data | |
| Senior Director of Finance & Investor Relations | no data | no data | no data | |
| Senior VP & Chief Legal Officer | no data | no data | no data | |
| Chief Human Resources Officer | 0.75yr | no data | no data | |
| Senior Vice President of Immunogenetics | 2.25yrs | no data | no data |
2.3yrs
Average Tenure
60yo
Average Age
Experienced Management: EDIT's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.83yrs | US$14.49m | 0.023% $ 1.1m | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Co-Founder & Scientific Advisory Board Member | no data | no data | no data | |
| Independent Chairman | 2.83yrs | US$260.75k | 0.016% $ 761.2k | |
| Independent Director | 4.5yrs | US$210.25k | 0% $ 0 | |
| Independent Director | 3.67yrs | US$215.25k | 0.0032% $ 152.0k | |
| Independent Director | 2.92yrs | US$226.52k | 0.027% $ 1.3m | |
| Independent Director | 1.92yrs | US$370.65k | 0% $ 0 | |
| Director | 0.083yr | no data | no data |
2.8yrs
Average Tenure
61yo
Average Age
Experienced Board: EDIT's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: EDIT insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.9%.
Top Shareholders
Company Information
Editas Medicine, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Editas Medicine, Inc.
- Ticker: EDIT
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$4.707b
- Shares outstanding: 61.82m
- Website: https://www.editasmedicine.com
Number of Employees
Location
- Editas Medicine, Inc.
- 11 Hurley Street
- Cambridge
- Massachusetts
- 2141
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| EDIT | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Feb 2016 |
| 8EM | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2016 |
| 0IFK | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Feb 2016 |
Biography
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a pr...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/18 23:14 |
| End of Day Share Price | 2021/01/15 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.